导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.73% | 1184/3712 |
| 近一周 | -1.59% | 1788/4228 |
| 近一月 | -3.60% | 2064/4196 |
| 近一季 | -10.03% | 2818/4044 |
| 近半年 | -3.45% | 1946/3824 |
| 近一年 | 7.84% | 1087/3446 |
| 近两年 | 60.74% | 957/2399 |
| 近三年 | 36.64% | 655/1802 |
| 成立以来 | 142.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.88% 1419/4961 |
20.64% 1214/5312 |
- - |
- - |
| 2025 | 29.89% 1367/4813 |
2.92% 1236/3635 |
1.89% 2041/4076 |
23.74% 1518/4524 |
0.09% 2226/4813 |
| 2024 | 3.40% 1929/3463 |
0.61% 950/2808 |
-5.72% 1788/3014 |
12.02% 2429/3129 |
-2.68% 2159/3463 |
| 2023 | -0.76% 472/2656 |
8.80% 444/2280 |
-4.06% 1028/2385 |
-3.02% 825/2515 |
-1.98% 399/2655 |
| 2022 | -17.89% 636/2207 |
-11.99% 561/1919 |
2.53% 1290/2016 |
-9.28% 266/2113 |
0.31% 1510/2208 |
| 2021 | 18.97% 200/1822 |
2.44% 218/1255 |
10.54% 455/1330 |
3.65% 398/1466 |
1.36% 955/1822 |
| 2020 | 32.37% 486/1250 |
-1.48% 222/1028 |
21.10% 248/1067 |
7.15% 800/1164 |
3.54% 908/1184 |
| 2019 | 29.99% 491/1092 |
23.64% 547/739 |
-7.29% 547/788 |
4.67% 187/850 |
8.35% 324/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 安信中证500指数增强C VS. 长安沪深300非周期A(740101) |